Product logins

Find logins to all Clarivate products below.


Urological Devices | Market Insights | Europe | 2020

The European urological device market will grow marginally through 2028. Revenue growth will be driven by ongoing product innovation and an increasing aging population and an associated rise in cases of urological diseases such as UI, stones, BPH, prostate and bladder cancer, and ED; however, limited capital equipment budgets among European health care facilities and prevailing preferences for established treatment methods will hinder the adoption of newer, premium-priced technology to some degree, hampering overall market growth.

This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for urological devices in France, Germany, Italy, Spain, and the UK across a 10-year period.

Related Medtech Insights Reports

Report
Interventional Cardiology Devices – Market Insights – Europe
The European interventional cardiology device market is highly competitive and poised for moderate growth over the forecast period, driven by increasing PCI volumes for complex CAD cases and the…
Report
Electrophysiology Mapping and Ablation Devices – Market Insights – Europe
The European EP mapping and ablation device market will grow moderately through 2035, driven by the rising prevalence of cardiac arrhythmias, improved access to treatment, advancements in ablation…
Report
Aortic Repair Devices – Market Insights – Europe
The European aortic stent graft market is the primary driver of growth in the aortic repair device market and will drive revenue expansion over the forecast period, supported by ongoing innovation…
Report
Cardiac Rhythm Management Devices – Market Insights – Europe
The European CRM device market will continue to grow modestly over the forecast period because of rising ICM procedure volumes, the introduction of dual-chamber leadless pacemakers, and increased…
Report
Gastrointestinal Endoscopy Devices – Market Insights – Europe
The European GI endoscopy device market will be driven primarily by the high incidence of gastric cancer and CRC in the region. Market growth will be supported by nationwide CRC and GI cancer…